发布求助
文献互助 智能选刊 最新文献

Onco Zine - The International Oncology Network最新文献

筛选
英文 中文
Modeling Barrett’s Esophagus on a Personalized Organ Chip 用个性化器官芯片模拟巴雷特食道
Onco Zine - The International Oncology Network Pub Date : 2023-06-09 DOI: 10.14229/onco.2023.06.09.009
B. Boettner
{"title":"Modeling Barrett’s Esophagus on a Personalized Organ Chip","authors":"B. Boettner","doi":"10.14229/onco.2023.06.09.009","DOIUrl":"https://doi.org/10.14229/onco.2023.06.09.009","url":null,"abstract":"Acid reflux, the backwash of stomach acid into the swallowing tube, or esophagus, is something that many experience occasionally. When it happens repeatedly and becomes a chronic problem, it can result in “Barrett’s esophagus” (BE), a condition in which cells in the epithelial lining of the esophagus appear to assume the identity of stomach or intestine cells. This process is known as “metaplasia” and is associated with an increased incidence of esophageal cancer – one of the deadliest tumors estimated to be the sixth most common cause of cancer deaths worldwide.","PeriodicalId":301285,"journal":{"name":"Onco Zine - The International Oncology Network","volume":"71 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124574186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
It’s Time to Stop Talking About Cellular Therapy Disparities and Take Action 是时候停止谈论细胞治疗差异并采取行动了
Onco Zine - The International Oncology Network Pub Date : 2023-05-22 DOI: 10.14229/onco.2023.05.22.001
J. Auletta, S. Davies
{"title":"It’s Time to Stop Talking About Cellular Therapy Disparities and Take Action","authors":"J. Auletta, S. Davies","doi":"10.14229/onco.2023.05.22.001","DOIUrl":"https://doi.org/10.14229/onco.2023.05.22.001","url":null,"abstract":"The cellular therapy community has long recognized inequality in access to treatment and disparities in treatment outcomes based on patient race, ethnicity, and socioeconomic status. It is no longer enough to recognize the problem exists. As the late John Lewis stated, “If you see something that is not right, not fair, not just, you have a moral obligation to do something about it.” The cellular therapy community, which includes hematopoietic cell transplantation (HCT), must advance efforts to end these inequities.","PeriodicalId":301285,"journal":{"name":"Onco Zine - The International Oncology Network","volume":"820 ","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133848696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
“If I Can See It, I Can Kill It” “如果我能看到它，我就能杀死它”
Onco Zine - The International Oncology Network Pub Date : 2023-05-19 DOI: 10.14229/onco.2023.05.19.001
A. Pecora
{"title":"“If I Can See It, I Can Kill It”","authors":"A. Pecora","doi":"10.14229/onco.2023.05.19.001","DOIUrl":"https://doi.org/10.14229/onco.2023.05.19.001","url":null,"abstract":"If one could use the word “elegant” to describe anticancer therapy, that moniker would apply to messenger RNA (mRNA) vaccines. The elegance of mRNA vaccines derives from their apparent ability to overcome one of the major limitations of conventional cancer vaccines: HLA restriction. Most cancer vaccines are composed of glycoproteins that only fit inside the antigen-presenting pockets in human leucocyte antigen (HLA) molecules – our cellular “home address” – a certain percentage of the time. Consequently, anyone treated with a protein-based vaccine is fortunate to achieve an immune response.","PeriodicalId":301285,"journal":{"name":"Onco Zine - The International Oncology Network","volume":"45 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124733240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Road to the Clinic: BYON4228 通往诊所之路:BYON4228
Onco Zine - The International Oncology Network Pub Date : 2023-05-03 DOI: 10.14229/onco.2023.05.03.001
M. Timmers, T. K. van den Berg
{"title":"The Road to the Clinic: BYON4228","authors":"M. Timmers, T. K. van den Berg","doi":"10.14229/onco.2023.05.03.001","DOIUrl":"https://doi.org/10.14229/onco.2023.05.03.001","url":null,"abstract":"The latest Byondis investigative therapy that will soon enter Phase I or First-in-Human (FiH) study is also the company’s first immuno-oncology (IO) therapeutic, BYON4228. How and why it got there is the stuff that researchers’ dreams are made of. BYON4228 is a monoclonal antibody (mAb). A mAb is – per the US National Cancer Institute (NCI), “a type of protein that is made in the laboratory and can bind to certain targets in the body, such as antigens on the surface of cancer cells.” Monoclonal antibodies can be used to diagnose and treat many diseases, such as cancers. They can be used alone or to carry drugs, toxins, or radioactive substances directly to cancer cells","PeriodicalId":301285,"journal":{"name":"Onco Zine - The International Oncology Network","volume":"47 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132793181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Updated Data to be Presented at ASH Reinforces the Strength of Servier’s Hematology Portfolio 在ASH上公布的最新数据增强了施维雅血液学产品组合的实力
Onco Zine - The International Oncology Network Pub Date : 2021-12-10 DOI: 10.14229/onco.2021.12.10.001
Peter Hofland
{"title":"Updated Data to be Presented at ASH Reinforces the Strength of Servier’s Hematology Portfolio","authors":"Peter Hofland","doi":"10.14229/onco.2021.12.10.001","DOIUrl":"https://doi.org/10.14229/onco.2021.12.10.001","url":null,"abstract":"First results from the Phase 3 AGILE study, a multicenter, double-blind, randomized, placebo-controlled clinical trial in patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1-) mutation shows improved event-free survival (EFS) and various secondary outcomes.","PeriodicalId":301285,"journal":{"name":"Onco Zine - The International Oncology Network","volume":"53 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129842525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
How Good Communication and Transparency may Help avoid a Medical Malpractice Lawsuits 良好的沟通和透明度如何有助于避免医疗事故诉讼
Onco Zine - The International Oncology Network Pub Date : 2021-02-10 DOI: 10.14229/onco.2021.02.10.001
Peter Hofland
{"title":"How Good Communication and Transparency may Help avoid a Medical Malpractice Lawsuits","authors":"Peter Hofland","doi":"10.14229/onco.2021.02.10.001","DOIUrl":"https://doi.org/10.14229/onco.2021.02.10.001","url":null,"abstract":"In the Hippocratic Oath, Physicians promise to behave ethically and professionally towards their patients. However, in complex care settings, physicians may default to practicing behavior that, in essence, runs counter to the interests of a patient. Results from a study published in BMC Health Services Research suggests that this may include practicing defensive medicine, failing to report incidents, and being hesitant to disclose incidents to patients.","PeriodicalId":301285,"journal":{"name":"Onco Zine - The International Oncology Network","volume":"11 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132751976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Knowledge Alone is Not Enough to Defeat Cancer 仅凭知识不足以战胜癌症
Onco Zine - The International Oncology Network Pub Date : 2018-11-02 DOI: 10.14229/onco.2018.11.02.001
Peter Hofland
{"title":"Knowledge Alone is Not Enough to Defeat Cancer","authors":"Peter Hofland","doi":"10.14229/onco.2018.11.02.001","DOIUrl":"https://doi.org/10.14229/onco.2018.11.02.001","url":null,"abstract":"Doctors should have the liberty to treat patients as they thinks best, and that they should be able to practice medicine without fear of litigation for failure to comply with, what he calls 'arbitrary,' standards and guidelines that may not always be appropriate for every patient. Excessive and unnecessary regulatory requirements and insurance demands make doctors less flexible and effective in treating their patients.","PeriodicalId":301285,"journal":{"name":"Onco Zine - The International Oncology Network","volume":"25 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123917796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Time to Progression of Colorectal Cancer may be Predicted by Model Based on Serial Liquid Biopsy 基于连续液体活检的模型可以预测结直肠癌的进展时间
Onco Zine - The International Oncology Network Pub Date : 2018-08-31 DOI: 10.14229/onco.2018.08.31.001
Peter Hofland
{"title":"Time to Progression of Colorectal Cancer may be Predicted by Model Based on Serial Liquid Biopsy","authors":"Peter Hofland","doi":"10.14229/onco.2018.08.31.001","DOIUrl":"https://doi.org/10.14229/onco.2018.08.31.001","url":null,"abstract":"While clinicians often use tumor biopsies for cancer genotyping, many tumors have intratumor heterogeneity which can drive treatment resistance; therefore, multiple biopsies in time and space are needed to better understand how tumors evolve to resist therapy.","PeriodicalId":301285,"journal":{"name":"Onco Zine - The International Oncology Network","volume":"152 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134268849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Liquid Biopsies and Treatment Response 液体活检和治疗反应
Onco Zine - The International Oncology Network Pub Date : 2017-06-30 DOI: 10.14229/onco.2017.06.30.001
Peter Hofland
{"title":"Liquid Biopsies and Treatment Response","authors":"Peter Hofland","doi":"10.14229/onco.2017.06.30.001","DOIUrl":"https://doi.org/10.14229/onco.2017.06.30.001","url":null,"abstract":"Understanding the mechanisms of acquired resistance to targeted therapies in the treatment of cancer may help guide treatment strategies and improve clinical outcomes. [A new study, presented at the 19th World Congress on Gastrointestinal Cancer of the European Society of Medical Oncology (ESMO) shows that so-called liquid biopsies, blood tests that detect circulating tumor DNA (ctDNA), may not only sound an early alert that a treatment?s effect is diminishing, but may also help explain why – sometimes offering clues about what to do next.","PeriodicalId":301285,"journal":{"name":"Onco Zine - The International Oncology Network","volume":"32 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2017-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133426817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信
小红书